Avadel Pharmaceuticals AVDL

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.03 (+0.38%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Avadel Pharmaceuticals (AVDL)
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $7.91

  • Market Cap

    $764.34 Million

  • Price-Earnings Ratio

    -10.55

  • Total Outstanding Shares

    96.63 Million Shares

  • Total Employees

    188

  • Dividend

    No dividend

  • IPO Date

    June 7, 1996

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    Block 10-1 blanchardstown corporate park, Dublin, L2, 15

  • Homepage

    https://www.avadel.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities, Continuing$-6.02 Million
Net Cash Flow From Operating Activities$-82.81 Million
Net Cash Flow$-23.23 Million
Exchange Gains/Losses$806,000
Net Cash Flow From Operating Activities, Continuing$-82.81 Million
Net Cash Flow From Investing Activities, Continuing$64.80 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Basic Average Shares$97.96 Million
Net Income/Loss Available To Common Stockholders, Basic$-72.58 Million
Net Income/Loss Attributable To Parent$-72.58 Million
Cost Of Revenue$11.16 Million
Selling, General, and Administrative Expenses$177.72 Million
Income/Loss From Continuing Operations Before Tax$-73.00 Million

Comprehensive Income

October 1, 2023 to September 30, 2024
MetricValue
Other Comprehensive Income/Loss$-70.43 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Comprehensive Income/Loss Attributable To Parent$-70.43 Million
Other Comprehensive Income/Loss Attributable To Parent$2.15 Million
Comprehensive Income/Loss$-70.43 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Current Assets$127.26 Million
Current Liabilities$42.78 Million
Equity Attributable To Noncontrolling Interest$0
Accounts Payable$7.92 Million
Noncurrent Liabilities$40.81 Million
Liabilities$83.59 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about AVDL from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.